Open AccessPharmacoeconomic models in rheumatology
Author(s) -
Konstantin Tachkov,
Vladimira Boyadzhieva,
Zornitsa Mitkova,
Nikolay Stoilov,
Guenka Petrova
Publication year - 2021
Publication title -
revmatologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.1
H-Index - 15
eISSN - 2738-831X
pISSN - 1310-0505
DOI - 10.35465/29.4.2021.pp15-39
Subject(s) - medicine , rheumatology , pharmacoeconomics , rheumatoid arthritis , intensive care medicine , physical therapy , medical physics
Pharmacoeconomic models of chronic diseases explore the development of the disease, patients’ pathways through it and calculate the cost-effectiveness of the therapy with different medicines. The goal of the current study is to identify the pharmacoeconomic models used in rheumatology, their historical development and utilization. Systematic search in PubMed was performed with key words „pharmacoeconomic, models, rheumatology, and cost-effectiveness “. On total 58 manuscripts were identified, describing mainly the rheumatoid arthritis development. The first one in line is the ACCES model of rheumatoid arthritis which have been validated in Sweden, Norway, etc. This is one of the first Markov model in rheumatology. Biological medicines are in the primary area of interest for modelling their therapeutic results. During the latest year scientists are working for the development of the web based platform to forecast the biological therapy (model PREDIRA). In alliance with other therapeutic areas with the development of artificial intelligence the pharmacoeconomic models is expected to increase, especially those build with data from real world clinical practice.